Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Stefan Heymel"'
Autor:
Konrad Kirsch, Stefan Heymel, Albrecht Günther, Kathleen Vahl, Thorsten Schmidt, Dominik Michalski, Michael Fritzenwanger, Paul Christian Schulze, Rüdiger Pfeifer
Publikováno v:
BMC Neurology, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background This study aimed to assess the prognostic value regarding neurologic outcome of CT neuroimaging based Gray-White-Matter-Ratio measurement in patients after resuscitation from cardiac arrest. Methods We retrospectively evaluated CT
Externí odkaz:
https://doaj.org/article/5a62108f14ab4b13af3cf9ba4136e710
Autor:
Friederike Klein, Sven Möbius-Winkler, Laura Bäz, Rüdiger Pfeifer, Michael Fritzenwanger, Stefan Heymel, Marcus Franz, Pawel Aftanski, P. Christian Schulze, Daniel Kretzschmar
Publikováno v:
Canadian Respiratory Journal, Vol 2022 (2022)
Background. Percutaneous catheter-based ultrasound-assisted thrombolysis (UACDT) is recommended for patients with intermediate-high-risk or high-risk pulmonary embolism (PE) in whom systemic thrombolysis has failed or is contraindicated. Aim. To eval
Externí odkaz:
https://doaj.org/article/0f158b29525345e4959fc04095f644e7
Autor:
Friederike, Klein, Sven, Möbius-Winkler, Laura, Bäz, Rüdiger, Pfeifer, Michael, Fritzenwanger, Stefan, Heymel, Marcus, Franz, Pawel, Aftanski, P Christian, Schulze, Daniel, Kretzschmar
Publikováno v:
Canadian respiratory journal. 2022
Percutaneous catheter-based ultrasound-assisted thrombolysis (UACDT) is recommended for patients with intermediate-high-risk or high-risk pulmonary embolism (PE) in whom systemic thrombolysis has failed or is contraindicated.To evaluate the safety an
Publikováno v:
EuroIntervention. 10:640-645
Aims Renal denervation (RDN) with radiofrequency (RF) is being used to treat resistant hypertension (rHTN). As 15-30% of treated patients are non-responders to RDN, we investigated whether RDN with cryoenergy can serve as a second-line option. Method
Publikováno v:
International Journal of Cardiology. 168:3130-3132
Arterial hypertension (HTN) is one of themost important risk factors of cardiovascular diseases [1,2]. Patients, in whom the pharmacological therapy fails to reduce theblood pressure (BP) below140/90 mmHg, are considered to have resistant HTN [2,3].